Date: Thu, 18 Dec 1997 18:19:43 GMT Server: Apache/1.0.5 Content-type: text/html Content-length: 4927 Last-modified: Mon, 06 Oct 1997 21:48:17 GMT
1996 highlights |
||
* January Acquired exclusive rights to XTL Biopharmaceutical's TrimeraXTL technology for developing ACT therapies and human monoclonal antibodies. * March Initial RIGScan® CR49 results of pivotal multicenter trials reported at the Society of Surgical Oncology's annual meeting, showing that the RIGS procedure helped surgeons find additional cancer in a significant number of patients. * April Completed a successful $32.4 million public offering involving the sale of 1.75 million shares of Neoprobe common stock. Formed a joint venture with Peptor Ltd. to develop radiolabeled, small, stable peptide analogs as cancer detection and treatment products. * May Patent granted to National Cancer Institute and University of Nebraska Medical Center researchers covering a large group of second-generation monoclonal antibodies, including the CC49 component of Neoprobe's lead product, RIGScan CR49. Secured licenses to a portfolio of 120 patents from The Dow Chemical Company covering chelation technology and radioimmunotherapy. Filed Neoprobe's first marketing application, or "dossier," for RIGScan CR49 to the European regulatory authorities. * June Entered into an agreement to use the cGMP cell processing facilities of Cellcor for RIGS/ACTTM. * July Dossier accepted for review by European regulatory authorities, one of the first of its kind reviewed under the new centralized European Union procedures. * August Acquired from Biomira Inc. an exclusive worldwide license for use of Biomira's MAb-170 for the surgical detection of breast cancer and options to additional antibodies. Coordinated a RIGS technology and lymphatic mapping symposium at the 8th Congress of the European Society of Surgical Oncology in Dublin, Ireland. * September Signed a unique agreement with United States Surgical Corporation for marketing RIGS surgical cancer detection products. * October Cancer researcher John Daly, M.D., Cornell University Medical Center, New York Hospital, presented Phase III data for RIGScan CR49 at the American College of Surgeons annual meeting. * November Completed enrollment and participation of 287 patients in a Phase III trial for RIGScan CR49 for primary colorectal cancer. Garnered approximately $15 million from the exercise of over 99% of 2,330,000 Series E warrants which expired November 12. Announced beginning of a multiphase initiative for breast cancer diagnosis and treatment, opening a Phase I study for RIGS surgical detection and a pilot study for activated cellular therapy and supporting intraoperative lymphatic mapping research with use of the Neoprobe® 1000 device. * December Submitted the company's first Biologics License Application (BLA) to the United States FDA for RIGScan CR49. * January 1997 Received marketing approval in South Korea for RIGScan CR49. |
![]() |
![]() ![]() |
![]() |